



Published in final edited form as:

J Vasc Surg. 2022 May ; 75(5): 1762–1775. doi:10.1016/j.jvs.2021.11.057.

A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia

Philip Goodney, MD, MS^a, Samir Shah, MD^b, Yiyuan David Hu, BA^c, Bjoern Suckow, MD, MS^a, Scott Kinlay, MD^d, David G. Armstrong, DPM, MD, PhD^e, Patrick Geraghty, MD^f, Megan Patterson, MBA^g, Matthew Menard, MD^h, Manesh R. Patel, MDⁱ, Michael S. Conte, MD^j

^aVascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon

^bVascular Surgery, University of Florida, Gainesville

^cGeisel School of Medicine, Dartmouth Hitchcock Medical Center, Lebanon

^dCardiovascular Medicine, Boston Medical Center, Boston

^eDepartment of Surgery, Keck School of Medicine of University of Southern California, Los Angeles

^fVascular Surgery, Washington University in St. Louis, St. Louis

^gVascularCures Foundation, Redwood City

^hVascular Surgery, Brigham and Women's Hospital, Boston

ⁱDuke University Medical Center, Durham

^jVascular Surgery, University of California, San Francisco, San Francisco

Abstract

Chronic limb-threatening ischemia (CLTI) causes significant morbidity with profound negative effects on health-related quality of life. As the prevalence of peripheral artery disease and diabetes

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Correspondence: Philip Goodney, MD, 1 Medical Center Dr, Lebanon, NH 03765 (philip.goodney@hitchcock.org).

AUTHOR CONTRIBUTIONS

Conception and design: PG, SS, BS, SK, DG, PG, MPatT, MM, MPate, MC

Analysis and interpretation: PG, SS, BS, SK, DG, PG, MPatT, MM, MPate, MC

Data collection: PG, SS, YH, BS, SK, DG, PG, MPatT, MM, MPate, MC

Writing the article: PG, SS, YH, BS, SK, DG, PG, MPatT, MM, MPate, MC

Critical revision of the article: PG, SS, YH, BS, SK, DG, PG, MPatT, MM, MPate, MC

Final approval of the article: PG, SS, YH, BS, SK, DG, PG, MPatT, MM, MPate, MC

Statistical analysis: PG, SS, YH, SK, DG, PG, MPatT, MM, MPate, MC

Obtained funding: Not applicable

Overall responsibility: PG

Author conflict of interest: D.G.A. was partially supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Award Number 1R01124789-01A1." P.G. was partially supported by a Strategically Focused Research Network Grant from the American Heart Association (18SFRN33900085). M.M. reports a role on the Advisory Board for Janssen, Inc., and Angen. M.R.P. reports conflicts from Bayer, Janssen, Amgen, and Heartflow, and Research Grants from the NHLBI and Medtronic. M.S.C. reports conflicts from an Advisory Board role from Abbott Vascular, and Angen. P.G. reports conflicts from Bard, Boston Scientific, and equity shares in Pulse Therapeutics and MedAlliance.

Additional material for this article may be found online at www.jvascsurg.org.

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

continue to rise in our aging population, the public health impact of CLTI has escalated. Patient-reported outcome measures (PROMs) have become common and important measures for clinical evaluation in both clinical care and research. PROMs are important for the measurement of clinical effectiveness and cost effectiveness and for shared decision-making on treatment options. However, the PROMs used to describe the experience of patients with CLTI are heterogeneous, incomplete, and lack specific applicability to the underlying disease processes and diverse populations. For example, certain PROMs exist for patients with extremity wounds, and other PROMs exist for patients with pain, and still others exist for patients with vascular disease. Despite this multiplicity of tools, no single PROM encompasses all of the components necessary to describe the experiences of patients with CLTI. This significant unmet need is evident from both published reports and contemporary large-scale clinical trials in the field. In this systematic review, we review the current use of PROMs for patients with CLTI in clinical practice and in research trials and highlight the gaps that need to be addressed to develop a unifying PROM instrument for CLTI. (*J Vasc Surg* 2022;75:1762–75.)

Keywords

Peripheral artery disease; Chronic limb-threatening ischemia; Critical limb ischemia; Amputation; Patient reported outcome; Decision aid; Decision tool; Surgical decision; Surgical decision-making; Shared decision-making

Peripheral artery disease (PAD) is estimated to affect more than 200 million individuals around the globe, with an incidence increasing owing to aging, diabetes, lifestyle, and environmental factors.¹ The most severe manifestation of PAD is chronic limb-threatening ischemia (CLTI; also referred to as “critical limb ischemia” or CLI), where severe vascular insufficiency leads to disabling pain, wounds, and gangrene of the lower limb. CLTI incurs significant mortality, morbidity, and negative effects on physical function and health-related quality of life (HRQoL). Patients with CLTI often have other significant comorbidities and are at increased risk for both mortality and major amputation (each estimated at 22% at 1 year).^{2,3} The management of these patients is multimodal, often requiring medical therapy, analgesics, wound care, revascularization, and associated surgical procedures such as minor and major amputation. Frequently multiple providers are involved in the care of patients with CLTI. Decision-making for individual patients with CLTI is a complex balance of estimated risks and benefits, inadequately informed by high-quality evidence. Recent and ongoing clinical trials are attempting to address this evidence gap, while contemporary practice guidelines promote greater standardization in evaluation and treatment.^{4–8}

Patient-reported outcome measures (PROMs) have become an essential component of scientific evaluation of medical practice.^{9,10} Although once limited to QoL instruments pursued only in the context of large clinical trials, PROMs now are commonplace in the treatment of many disease processes and have become a critical element of the evaluation of clinical practice and the value of care.^{11–16} PROMs may be used to measure clinical and cost-effectiveness of treatment strategies, and to help guide shared decision-making. In certain treatment settings, such as transcatheter aortic valve replacement, the use of patient

decision support has been discussed as a necessary adjunct for payer reimbursement, and similar directions may lie ahead for PROMs.

However, no single validated PROM exists for patients with CLTI. Many different phenotypes exist within the spectrum of CLTI, such as neuropathic ulcers among patients with diabetes and varying degrees of PAD, in contrast with smokers with distal tissue loss specifically attributable to severe arterial insufficiency. Each patient has a different presentation, risk of limb loss, risk/benefit for treatment, and a different potential impact on their HRQoL. This clinical heterogeneity is the central tenet that underlies the challenge of developing a unifying PROM for CLTI. Other factors contribute to this challenge as well, including the complexity inherent in instrument development and the resource investment required by the stakeholders involved in the care of patients with CLTI.

To better understand the current landscape of PROMs for patients with CLTI, we conducted a systematic review of published studies in the field. This work involved first identifying each PROM and outlining the specific domains measured within the PROM. Second, we detailed how each PROM or group of PROMs has been used in studies of patients with CLTI over time. Finally, we outline how the frameworks created by these efforts may help point the way toward the development of a unified, validated PROM for CLTI.

METHODS

On January 14, 2019, a multidisciplinary group of clinicians, scientists, regulatory experts, and patients met in Washington, DC, convened by Vascular Cures (a 501(c)3 nonprofit foundation in Redwood City, CA) to discuss the current state of PROMs for patients with PAD. After these discussions, the group agreed that a contemporary review of the available PROMS for patients with CLTI was needed and a working group effort was launched.

We performed a systematic literature review of PROMs used in studies of patients with CLTI. A simple search strategy was designed and executed as outlined below. Our search spanned publications from 1990 to the end of calendar year 2020, and were limited to English articles on PUBMED with a searchable abstract.

Search terms.

- “critical limb ischemia” OR “chronic limb threatening ischemia” and
- “quality of life”
(any field, PUBMED, English language)

This search strategy was supplemented by abstract review and discussion among the authors of other studies known to have used a PROM in a population of patients with CLTI. A similar project convened by this group addressed claudication, and thus we limited this effort to critical limb ischemia.

Our initial search strategy initially identified 337 studies. Two authors reviewed the studies along with the HRQoL measures used within the study. Subsequently, members of the study team read each abstract identified in the search strategy. We kept only those studies that

(1) outlined a clinical series or group of patients with a CLTI diagnosis, and (2) had a QoL measure described within the abstract and body of the article. Studies that did not meet these criteria after review were not included (Appendix 1, online only). Studies that specifically commented on patients with critical limb ischemia, but also studied patients with claudication, were included with this review.

Once we had established our final study database, we took two key steps. First, we recorded the individual PROMs encountered across each study; these elements are outlined in Table I. Second, we then determined how these PROMs were used, individually and in combination, within the described research studies (Fig 1 and Appendix 2, online only).

A PRISMA 2020 Checklist was completed after the conclusion of the systematic review, in accordance with *Journal of Vascular Surgery* guidelines. The review was registered with the PRISMA site at the National Institute for Health Research in the United Kingdom (PROSPERO Registration Number 265034). All participants at the VascularCures PROM-PAD working group reviewed the study goals and protocol (Appendix 3, online only).

RESULTS

Number of studies identified in our systematic review.

We identified a total of 337 studies for inclusion. After review, from these 337 studies we formed our final selection of 99 individual publications, with the criteria that each study evaluated patients with CLTI and reported a PROM or a HRQoL metric. These studies were published between 1992 and 2020 and used more than 20 different established or derived PROMs or QoL measures (Appendix 2, online only).

Components of current PROMs in CLTI.

Table I summarizes six of the most used PROM instruments for patients with CLTI. Many of these assessment tools consider some aspects of CTLI, and their impact on HRQoL. For example, the WOUND-QoL PROM, developed in 2014, is a short assessment tool designed to capture many of the aspects of QoL that are affected by chronic wounds and was compiled from a review of three other existing wound evaluation tools to simplify this difficult assessment process.¹⁷ While it considers the effects of tissue loss and the pain associated with the wound, it is less precise in describing the effects on ambulatory function. There is a single question directly related to mobility (“Does the wound limit you in moving about?”), and similarly the impact of the wound on patient families and caregivers is only briefly explored. However, an advantage of WOUND-QoL when compared with its predecessors is that it is short—only 17 items in a short two-page questionnaire.

Other instruments have different characteristics. For example, the PADQOL instrument is longer, with 38 individual components, and includes domains related to fear or uncertainty.¹⁸ Other measures are especially brief and focus only on function, such as the Walking Impairment Questionnaire, which has 14 components, and assesses only the individual’s perception of their walking ability.¹⁹ The Walking Impairment Questionnaire has been broadly used in PAD research but most commonly in studies of intermittent claudication rather than CLTI.

Use of PROMs in CLTI studies over time.

Next, we examined the temporal patterns of PROM use in CLTI studies. As shown in Fig 1, the number of studies of patients with CLTI that report a PROM or QoL measure have increased exponentially in recent years. Studies of patients with CLTI reporting a PROM were uncommon in the 1990s and early 2000s, with fewer than five studies published per year before 2004. After 2004, the number of studies of patients with CLTI reporting a PROM increased and numbered nearly 10 studies per year for nearly all years from 2010 and thereafter.

Most studies in the early years, namely, between 1992 and 2002, used a single PROM (Appendix 2, online only). However, the number of studies which used multiple PROMs has increased over time, as shown in Appendix 2 (online only) and Fig 1. In Fig 1, we outline how commonly these measures were used over time, and how commonly multiple components were part of the scaling assessment effort for a PROM. The number of different PROMs used across the studies in each year is represented by the size of the circles in Fig 1 and conveys the increasing incidence of multiple PROM use apparent in review of Appendix 2 (online only). Although the size of the circles indicates the number of studies found which used a PROM, there is certainly heterogeneity in terms of how central the PROM element was in each study.

By 2020, 20 different studies using 10 different PROMs were published to communicate QoL information among patients with CLTI. The most commonly used PROMS were the World Health Organization Quality of Life BREF measure, the VascuQoL measure, the Short Form measures (SF-6, SF-8, SF-12, and SF-36), and the EQ-5D measures. These instruments have all been used collectively to describe the domains that affect patients with CLTI. There are other measures that are less commonly used, such as the Center for Epidemiological Studies Depression Scale, the Geriatric Depression Scale, and the Nottingham Health Profile. In total, more than 20 different measurement scales have been used to characterize PROMs for patients with CLTI.

Finally, there are several trials studying patients with CLTI which that either currently recruiting patients or have recently completed their enrollment (Table II). These trials generally have a limb-related primary outcome, such as major adverse limb event-free survival. However, all have incorporated QoL assessments in one form or another. BEST-CLI uses the EQ-5D measure, and BASIL-2 incorporates the European Quality of Life 5 level questionnaire, in addition to the SF-12, and other generic tools. Other studies, such as the Swedish Drug Elution Trial in Peripheral Artery Disease (SWEDEPAD-2), assess HRQoL with the VascuQoL-6, a disease-specific HRQoL instrument.

DISCUSSION

Summary of existing PROMs in CLTI.

Our comprehensive review demonstrates that the existing repository of PROMs for patients with CLTI is heterogeneous and lacks consistency, adequate validation, and complete coverage of all the domains of interest for CLTI patients. Unlike patients with claudication, where technology and patient avidity for HRQoL assessment for symptom abatement has

been a recent emphasis in both regulatory and other trials, PROMs in patients with CLTI have been much less well-studied. Given the inherent heterogeneity of CLTI and the challenges in measuring these outcomes in complex patients, a major task lies ahead in developing a uniform, validated approach for PROM collection in CLTI. Further, keeping the ability to make comparisons with broader, more generic measures may be helpful in contextualizing CLTI in comparison with other diseases. Our review demonstrates that this task still lies ahead for those who care for patients with CLTI, despite some progress in expanding the pool of potential instruments over the last two decades.

Generic QoL assessment tools, such as the EQ5-D and SF-12, are often used to characterize QoL and patient reported outcomes in CLTI (Fig 1; Appendix 2, online only). Simple, established measurement tools have certain advantages. The EQ-5D, developed in 1987, has been used in thousands of research studies, is short and efficient, and focuses on five domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. However, although it has a long track record and it is simple, many researchers believe it lacks the specificity necessary to understand the treatment pathways encountered by patients with CLTI. This lack of specificity is not unique to the EQ-5D or the SF-12. This limitation also exists in vascular instruments such as the VascuQoL, which is not calibrated to the type of limitations experienced by patients with CLTI. Similar weaknesses are also present in other measures such as PADQOL. The growing realization that no one satisfactory CLTI measure exists, we believe, is the reason underlying the growth in the number of measures used over time as shown in Fig 1.

Why the current tools are too generic for use in CLTI.

As outlined elsewhere in this article, the gaps in existing PROMs for patients with CLTI are related to specificity and the spectrum of symptoms encountered by patients facing this disease. The need for discrimination in these PROMs is vital, because any of the new treatments that will be tested in CLTI require a careful assessment of any treatment effect. Such treatments include the full range of medical, biologic, regenerative, revascularization, and nonrevascularization interventions currently available or under development for CLTI. Capturing these treatment effects will be difficult, if not impossible, if the assessment tools are too general in nature and do not fully explore the domains of PROMs. Detecting a signal of a treatment effect will require more precise assessment of domains, and assessment of other domains not measured by these tools. By designing more precise and descriptive PROMs with more relevant domains calibrated to the treatment effects likely to be seen in these patients, we will both better understand individual treatment effects, as well as better evaluate existing and new therapies in clinical trials. A sample of currently enrolling trials studying patients with CLTI and incorporating PROMs is shown in Table II.

How stakeholders can work to advance PROMs in CLTI.

The VascularCures Foundation has a dedicated interest in partnering with researchers, patients, and investigators who are committed to a better understanding of treatment outcomes in PAD. By convening a multidisciplinary group of clinician-scientists, researchers, patients, regulatory experts, and industry partners to perform comprehensive

review, we hope to develop a broad foundation which will provide solid footing for the emergence of a widely applicable, validated set of PROMs in CLTI.

PROMs for patients with CLTI will need to inform decisions affecting individuals, groups, and, most important, patients with CLTI. These discussions will be beneficial to inform patient decision-making when individuals consider treatment options. Further, PROMs will be needed when treatments are compared across different groups in clinical trials.^{20–23} Finally, the overall impact of systematic treatment of the comorbidities which often occurs concomitantly with CLTI, such as diabetes and smoking, may have small impact at the individual level. However, when examining small changes in QoL using accurate tools, differences may be detectable in large populations if the measures are precise and reproducible. Finally, ensuring that stakeholders contribute broadly from different populations will help to ensure that these new measures translate outcomes across race, ethnicity, sex, gender, and socioeconomic status.

The benefits of a unifying PROM for CLTI.

Despite the challenges of developing unifying PROMs for patients with CLTI, the benefits of a single systematic approach are obvious. Interoperability across research studies, ease of comparison of treatment effects, and clear clinical communication are only a few of the reasons why a single CLTI PROM would improve clinical care. However, achieving this goal would require a consistent definition of CLTI, and consistent measures to assess its impact, even across different patient populations.

In addition to having wounds with varying etiologies, patients with CLTI experience differing journeys that have a variable impact over time. Like congestive heart failure, CLTI is a chronic, disabling disease and recurrent exacerbations are common. Clinical events, often measured in survival analysis fashion, fail to fully capture the patient's trajectory. A patient with an ischemic ulcer will have severe pain and wounds, but these symptoms often abate rapidly after revascularization treatments. Another patient, such as one with a neuropathic ulcer, may have a more indolent course with fewer pain symptoms but frequent infections and recurrences. A facile and agile PROM for CLTI would reflect these changes over time and the impact of treatments on the overall course. It would enable researchers to better measure the burden of this chronic, disabling disease and the value of defined strategies of care.

PROMs for CLTI would help to raise public awareness for CLTI and its treatments.

Unlike many other disease processes such as cancer, heart disease, and obesity, CLTI remains poorly understood by the lay public.^{24–26} Few messages exist to inform public awareness about CLTI. Moreover, given the complexity of the disease process and its predilection for affecting patients of lower socioeconomic status, there has been little interest in the dissemination of messages about the prevention and treatment of CLTI.^{27,28} An important goal in the development of PROMs for patients with CLTI is to improve public awareness. A single PROM for CLTI would ease communication to the public and lay press and help to convey messages to support the development of treatments for all stages of the disease.

Potential domains measured in a novel PROM for CLTI.

The working group held extensive discussions and a brief Delphi processes to establish a preliminary list of key domains that would be considered in future work aimed at establishing a PROM specifically derived for assessment in patients with CLTI. This process included direct input from several patients. Several domains came to the fore: pain, mobility, wounds, patient and family support systems, psychological and mental health, and a patient-level experience measure related to overall social impact and QoL (Fig 2).^{29–31} The group's consensus was that each of these domains contributed in a distinct way toward QoL for patients with CLTI, and a PROM focused on this effort would need to adequately capture these elements.^{21,32–40} Finally, making certain a tool that could be completed accurately by a family member would also be a key contribution.

After extensive discussion to identify these domains, the group then discussed what steps would be next in formulating a validated and unifying CLTI instrument. As shown in Fig 3, the steps include initial data collection from focus groups, qualitative interviews to pilot survey design, and testing to final production and validation. Each of these steps can be a lengthy process involving patients at every juncture, a considerable task given the comorbidity profile of most patients with CLTI.

A pathway forward.

These qualitative experiments—further exploration of the domains in focus groups and qualitative interviews, construction of differing types of survey structures, and testing of the newly derived instruments for validity—will be the important next steps forward. Retrospective studies evaluating the literature and measures described to date, prospective studies collecting qualitative information and categorizing the domains precisely, and measure development and validation will need to be supported by pilot projects and grants, with the goal of arriving at a usable PROM for patients with CLTI to provide accurate patient-reported outcome assessment in both clinical and research settings.

We anticipate this process will evolve in a manner reflected by the US Food and Drug Administration Roadmap to Patient-Focused Outcome Assessment in Clinical Trials (Appendix 4, online only).⁴¹ Divided into three parts, this outline describes how understanding the condition, conceptualizing the benefit, and assessing the treatment outcomes can be an effective pathway toward developing these measures. Key terminology and domains would also need to be defined a priori as part of this process. Although the focus of the US Food and Drug Administration efforts are measures to be used in clinical trials, these measures can also likely translate into real-world practice. The creation of a measure that can reflect quality would help to orient outcome assessment in variety of research and quality assessment forums.⁴² An example in heart failure research is the Kansas City Cardiomyopathy questionnaire, which helped not only in clinical trial outcome assessment, but in quality comparisons across care systems as well.⁴³

Choosing these pilot projects will be an effort undertaken by VascularCures and other stakeholders convened for this forum. Broader support from specialty societies and national funding agencies such as the Agency for Healthcare Research and Quality and the National

Institutes of Health is sorely needed. By collaborating with experts from vascular surgery, vascular medicine, podiatry, wound care, endocrinology, qualitative science, survey design, and clinical research, investigators will have a broad range of critique and insight to develop the best possible measures.

Potential barriers to design and implementation of PROMs in CLTI.

The group convened agreed that many challenges would be present in pursuing these tasks (Table III). These challenges will range from surmounting logistical challenges of PROM design with frail vascular patients to determining the optimal length and reproducibility of a survey instrument in both research and clinical settings. However, the group agreed that a single measure was the optimal goal, and that careful diligence toward this goal would be the primary pathway forward. Further, the group agreed that post-design assessment of feasibility, content validity, repeatability, and implementation would be necessary metrics of success. In other words, if the tool is ultimately so complex that it could not be used in practice, then this exercise would be in vain. As such, engagement with experts in implementation science would likely follow construction of the final PROM instruments to facilitate their dissemination.

CONCLUSIONS

The existing tools used to measure PROMs in patients with CLTI are limited, and a single better PROM for CLTI is needed. Unlike patients with intermittent claudication, where recent data have focused on more consistent measures of patient symptoms, patients with CLTI demonstrate different challenges and significant clinical heterogeneity. In patients with CLTI, there has been greater use of less precise measures, and many studies have resorted to a multiplicity of measures to evaluate patient reported outcomes. Development of a single, validated PROM for patients with CLTI will undoubtedly necessitate multidisciplinary efforts, time and investment from many stakeholders. We unequivocally aim for this measure to be a collaborative effort across all specialty groups who care for patients with CLTI. However, the return on this investment will be a more focused and precise way to measure treatment effects and progress in the care of the growing number of patients afflicted with CLTI.

In 2019 Vascular Cures convened the Working Group on Patient-Reported Outcome Measures in PAD to address shortcomings in outcomes measures in PAD and CLTI. A multidisciplinary group of clinicians, scientists, regulatory experts, payers, industry leaders and patients came together over two years to drive consensus on the current state of outcome measures in claudication and chronic limb-threatening ischemia and identify priority projects to meaningfully advance the field for the benefit of all stakeholders.

Vascular Cures is a national nonprofit organization committed to reducing death and disability from vascular diseases by advancing patient-centered research, catalyzing breakthrough collaborations and empowering individuals on their vascular health journeys. Vascular Cures would like to thank all Working Group participants for their contribution to the discussion and final articles and acknowledge the industry sponsors who made this important work possible: Abbott Vascular, Amgen, Bayer, Boston Scientific, Cook

Medical, Gore, Janssen (J&J), and Medtronic. Further, the authors wish to acknowledge Victor Aboyans, Julie Prillinger (Abbott), Ebony Dashiell (FDA) and Michael Jaff (Boston Scientific) for their comments and critiques of the article.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Vascular Cures Foundation provided funding for a meeting where the concept of the article was developed.

REFERENCES

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;382:1329–40. [PubMed: 23915883]
2. Abu Dabrh AM, Steffen MW, Asi N, Undavalli C, Wang Z, Elamin MB, et al. Nonrevascularization-based treatments in patients with severe or critical limb ischemia. *J Vasc Surg* 2015;62:1330–9.e1313. [PubMed: 26409842]
3. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural history of untreated severe or critical limb ischemia. *J Vasc Surg* 2015;62:1642–51.e1643. [PubMed: 26391460]
4. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 aha/acc guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;69:e71–126. [PubMed: 27851992]
5. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 aha/acc guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2017;135:e726–79. [PubMed: 27840333]
6. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. ; GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery ESfVS, World Federation of Vascular S. Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 2019;58:S1–109.e133. [PubMed: 31182334]
7. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *J Vasc Surg* 2019;69:3S–125S.e140. [PubMed: 31159978]
8. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the spirit-pro extension. *JAMA* 2018;319:483–94. [PubMed: 29411037]
9. Flynn KE, Dombeck CB, DeWitt EM, Schulman KA, Weinfurt KP. Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions. *Clin Trials* 2008;5:575–86. [PubMed: 19029206]
10. Kandel H, Khadka J, Pesudovs K. Intensive blood-pressure treatment and patient-reported outcomes. *N Engl J Med* 2017;377:2096–7. [PubMed: 29182238]
11. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. Effect of intensive blood-pressure treatment on patient-reported outcomes. *N Engl J Med* 2017;377:733–44. [PubMed: 28834483]
12. Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier - the potential of patient-reported outcomes. *N Engl J Med* 2017;377:1309–12. [PubMed: 28976860]
13. Baumhauer JF. Patient-reported outcomes - are they living up to their potential? *N Engl J Med* 2017;377:6–9. [PubMed: 28679102]

14. Basch E. Patient-reported outcomes - harnessing patients' voices to improve clinical care. *N Engl J Med* 2017;376:105–8. [PubMed: 28076708]
15. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med* 2016;375:1425–37. [PubMed: 27626365]
16. Blome C, Baade K, Debus ES, Price P, Augustin M. The “Wound-QOL”: a short questionnaire measuring quality of life in patients with chronic wounds based on three established diseasespecific instruments. *Wound Repair Regen* 2014;22:504–14. [PubMed: 24899053]
17. Treat-Jacobson D, Lindquist RA, Witt DR, Kirk LN, Schorr EN, Bronas UG, et al. The PADQOL: development and validation of a pad-specific quality of life questionnaire. *Vasc Med* 2012;17:405–15. [PubMed: 23184901]
18. Nicolai SP, Kruidenier LM, Rouwet EV, Graffius K, Prins MH, Teijink JA. The walking impairment questionnaire: an effective tool to assess the effect of treatment in patients with intermittent claudication. *J Vasc Surg* 2009;50:89–94. [PubMed: 19563956]
19. Villarreal MF, Siracuse JJ, Menard M, Assmann SF, Siami FS, Rosenfield K, et al. Enrollment obstacles in a randomized controlled trial: a performance survey of enrollment in BEST-CLI sites. *Ann Vasc Surg* 2020;62:406–11. [PubMed: 31491479]
20. Jones DW, Farber A. Review of the global vascular guidelines on the management of chronic limb-threatening ischemia. *JAMA Surg* 2020;155:161–2. [PubMed: 31851292]
21. Menard MT, Farber A, Assmann SF, Choudhry NK, Conte MS, Creager MA, et al. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) trial. *J Am Heart Assoc* 2016;5.
22. Kalbaugh CA, Loehr L, Wruck L, Lund JL, Matsushita K, Bengtson LGS, et al. Frequency of care and mortality following an incident diagnosis of peripheral artery disease in the inpatient or outpatient setting: the ARIC (atherosclerosis risk in communities) study. *J Am Heart Assoc* 2018;7.
23. Cronin CT, McCartan DP, McMonagle M, Cross KS, Dowdall JF. Peripheral artery disease: a marked lack of awareness in Ireland. *Eur J Vasc Endovasc Surg* 2015;49:556–62. [PubMed: 25736513]
24. Norgren L, Hiatt WR, Dormandy JA, Hirsch AT, Jaff MR, Diehm C, et al. The next 10 years in the management of peripheral artery disease: perspectives from the ‘PAD 2009’ conference. *Eur J Vasc Endovasc Surg* 2010;40:375–80. [PubMed: 20554459]
25. Laws RA, Fanaian M, Jayasinghe UW, McKenzie S, Passey M, Davies GP, et al. Factors influencing participation in a vascular disease prevention lifestyle program among participants in a cluster randomized trial. *BMC Health Serv Res* 2013;13:201. [PubMed: 23725521]
26. Johnsen MC, Landow WJ, Sonnefeld J, McClenny TE, Beatty PT, Raabe RD. Evaluation of legs for life national screening and awareness program for peripheral vascular disease: results of a follow-up survey of screening participants. *J Vasc Interv Radiol* 2002;13:25–35. [PubMed: 11788690]
27. Columbo JA, Davies L, Kang R, Barnes JA, Leinweber KA, Suckow BD, et al. Patient experience of recovery after major leg amputation for arterial disease. *Vasc Endovasc Surg* 2018;52:262–8.
28. Bartline PB, Suckow BD, Brooke BS, Kraiss LW, Mueller MT. Outcomes in critical limb ischemia compared by distance from referral center. *Ann Vasc Surg* 2017;38:122–9. [PubMed: 27531079]
29. Suckow BD, Goodney PP, Nolan BW, Veeraswamy RK, Gallagher P, Cronenwett JL, et al. Domains that determine quality of life in vascular amputees. *Ann Vasc Surg* 2015;29:722–30. [PubMed: 25725279]
30. Wijnand JGJ, van Koevorden ID, Teraa M, Spreen MI, Mali W, van Overhagen H, et al. Validation of randomized controlled trial-derived models for the prediction of postintervention outcomes in chronic limb-threatening ischemia. *J Vasc Surg* 2020;71:869–79. [PubMed: 31564582]
31. Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. *J Vasc Surg* 2018;68:624–33. [PubMed: 29804736]
32. Bunte MC, Shishehbor MH. Treatment of infrapopliteal critical limb ischemia in 2013: the wound perfusion approach. *Curr Cardiol Rep* 2013;15:363. [PubMed: 23605465]

33. Skrepnek GH, Mills JL Sr, Armstrong DG. A diabetic emergency one million feet long: disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the united states, 2006–2010. *PLoS One* 2015;10:e0134914. [PubMed: 26248037]
34. Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: part I. Pathophysiology and prevention. *J Am Acad Dermatol* 2014;70:1.e1–1.e18. quiz 19–20. [PubMed: 24355275]
35. Armstrong DG. An overview of foot infections in diabetes. *Diabetes Technol Ther* 2011;13:951–7. [PubMed: 21631279]
36. Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL Sr, Armstrong DG. Toe and flow: essential components and structure of the amputation prevention team. *J Vasc Surg* 2010;52:23S–7S. [PubMed: 20804929]
37. Wrobel JS, Chagares W, Stuck RM, Weaver F, Crews RT, Rapacki L, et al. Creating a diabetes foot reminder-based registry using the electronic medical record. *Inform Prim Care* 2010;18:283–7. [PubMed: 22040855]
38. Peters EJ, Childs MR, Wunderlich RP, Harkless LB, Armstrong DG, Lavery LA. Functional status of persons with diabetes-related lower-extremity amputations. *Diabetes Care* 2001;24:1799–804. [PubMed: 11574445]
39. US Food and Drug Administration. Roadmap to Patient Focused Outcome Measurement in clinical trials. Accessed 2019, www.Fda.Gov/media/87004/download.
40. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol* 2000;35:1245–55. [PubMed: 10758967]
41. Faller H, Steinbuechel T, Schowalter M, Spertus JA, Stork S, Angermann CE. [The Kansas City Cardiomyopathy Questionnaire (KCCQ) – a new disease-specific quality of life measure for patients with chronic heart failure]. *Psychotherapie, Psychosomatik, medizinische Psychologie* 2005;55:200–8. [PubMed: 15800814]
42. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the vascular quality of life questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. *J Vasc Surg* 2001;33:679–87. [PubMed: 11296317]
43. Coyne KS, Margolis MK, Gilchrist KA, Grandy SP, Hiatt WR, Ratchford A, et al. Evaluating effects of method of administration on walking impairment questionnaire. *J Vasc Surg* 2003;38:296–304. [PubMed: 12891111]
44. Jain A, Liu K, Ferrucci L, Criqui MH, Tian L, Guralnik JM, et al. The walking impairment questionnaire stair-climbing score predicts mortality in men and women with peripheral arterial disease. *J Vasc Surg* 2012;55:1662–73.e1662. [PubMed: 22608041]
45. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. *J Vasc Surg* 1998;28:1072–81. [PubMed: 9845659]
46. Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. *Am Heart J* 2004;147:301–8. [PubMed: 14760329]
47. Vileikyte L, Peyrot M, Bundy C, Rubin RR, Leventhal H, Mora P, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. *Diabetes Care* 2003;26:2549–55. [PubMed: 12941717]
48. Sommer R, Augustin M, Hampel-Kalthoff C, Blome C. The WOUND-QoL questionnaire on quality of life in chronic wounds is highly reliable. *Wound Repair Regen* 2017;25:730–2. [PubMed: 28857375]
49. Sommer R, Hampel-Kalthoff C, Kalthoff B, Neht C, Scherfer E, Winkler M, et al. Differences between patient- and proxy-reported HRQoL using the WOUND-QoL. *Wound Repair Regen* 2018;26:293–6. [PubMed: 30118159]
50. Seabrook GR, Cambria RA, Freischlag JA, Towne JB. Health-related quality of life and functional outcome following arterial reconstruction for limb salvage. *Cardiovasc Surg* 1999;7:279–86. [PubMed: 10386743]

51. Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. *J Vasc Surg* 1992;16:54–9. [PubMed: 1619725]
52. Thompson MM, Sayers RD, Reid A, Underwood MJ, Bell PR. Quality of life following infragenicular bypass and lower limb amputation. *Eur J Vasc Endovasc Surg* 1995;9:310–3. [PubMed: 7620957]
53. Chetter IC, Spark JI, Scott DJ, Kent PJ, Berridge DC, Kester RC. Prospective analysis of quality of life in patients following infrainguinal reconstruction for chronic critical ischaemia. *Br J Surg* 1998;85:951–5. [PubMed: 9692571]
54. Tretinyak AS, Lee ES, Kuskowski MM, Caldwell MP, Santilli SM. Revascularization and quality of life for patients with limb-threatening ischemia. *Ann Vasc Surg* 2001;15:84–8. [PubMed: 11221951]
55. Klevsgard R, Risberg BO, Thomsen MB, Hallberg IR. A 1-year follow-up quality of life study after hemodynamically successful or unsuccessful surgical revascularization of lower limb ischemia. *J Vasc Surg* 2001;33:114–22. [PubMed: 11137931]
56. Hallin A, Bergqvist D, Fugl-Meyer K, Holmberg L. Areas of concern, quality of life and life satisfaction in patients with peripheral vascular disease. *Eur J Vasc Endovasc Surg* 2002;24:255–63. [PubMed: 12217289]
57. Hernandez-Osma E, Cairols MA, Marti X, Barjau E, Riera S. Impact of treatment on the quality of life in patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2002;23:491–4. [PubMed: 12093063]
58. Thorsen H, McKenna S, Tennant A, Holstein P. Nottingham health profile scores predict the outcome and support aggressive revascularisation for critical ischaemia. *Eur J Vasc Endovasc Surg* 2002;23:495–9. [PubMed: 12093064]
59. Klevsgard R, Froberg BL, Risberg B, Hallberg IR. Nottingham health profile and short-form 36 health survey questionnaires in patients with chronic lower limb ischemia: before and after revascularization. *J Vasc Surg* 2002;36:310–7. [PubMed: 12170212]
60. Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, et al. Functional outcome in a contemporary series of major lower extremity amputations. *J Vasc Surg* 2003;38:7–14. [PubMed: 12844082]
61. Wann-Hansson C, Hallberg IR, Risberg B, Klevsgard R. A comparison of the Nottingham Health Profile and Short Form 36 health survey in patients with chronic lower limb ischaemia in a longitudinal perspective. *Health Qual Life Outcomes* 2004;2:9. [PubMed: 14969590]
62. Kugler CF, Rudofsky G. Do age and comorbidity affect quality of life or PTA-induced quality-of-life improvements in patients with symptomatic pad? *J Endovasc Ther* 2005;12:387–93. [PubMed: 15943516]
63. Deneuille M, Perrouillet A. Survival and quality of life after arterial revascularization or major amputation for critical leg ischemia in Guadeloupe. *Ann Vasc Surg* 2006;20:753–60. [PubMed: 16791454]
64. Durdu S, Akar AR, Arat M, Sancak T, Eren NT, Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. *J Vasc Surg* 2006;44:732–9. [PubMed: 16926085]
65. Engelhardt M, Bruijnen H, Scharmer C, Jezdinsky N, Wolfle K. Improvement of quality of life six months after infrageniculate bypass surgery: diabetic patients benefit less than non-diabetic patients. *Eur J Vasc Endovasc Surg* 2006;32:182–7. [PubMed: 16567116]
66. Kalbaugh CA, Taylor SM, Blackhurst DW, Dellinger MB, Trent EA, Youkey JR. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease. *J Vasc Surg* 2006;44:296–302; discussion: 302–3. [PubMed: 16814976]
67. Nguyen LL, Moneta GL, Conte MS, Bandyk DF, Clowes AW, Seely BL, et al. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. *J Vasc Surg* 2006;44:977–83; discussion: 983–4. [PubMed: 17098529]
68. Deutschmann HA, Schoellnast H, Temmel W, Deutschmann M, Schwantzer G, Fritz GA, et al. Endoluminal therapy in patients with peripheral arterial disease: prospective assessment of quality of life in 190 patients. *Am J Roentgenol* 2007;188:169–75. [PubMed: 17179360]

69. Keeling AN, Naughton PA, O'Connell A, Lee MJ. Does percutaneous transluminal angioplasty improve quality of life? *J Vasc Interv Radiol* 2008;19:169–76. [PubMed: 18341944]
70. Virkkunen J, Venermo M, Saarinen J, Keski-Nisula L, Apuli P, Kankainen AL, et al. Impact of endovascular treatment on clinical status and health-related quality of life. *Scand J Surg* 2008;97:50–5. [PubMed: 18450206]
71. Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. *Gene Ther* 2010;17:1152–61. [PubMed: 20393508]
72. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC, et al. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. *J Vasc Surg* 2010;52:843–9. e1. [PubMed: 20598482]
73. Iafrati MD, Hallett JW, Geils G, Pearl G, Lumsden A, Peden E, et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. *J Vasc Surg* 2011;54:1650–8. [PubMed: 22019148]
74. Pisa G, Reinhold T, Obi-Tabot E, Bodoria M, Bruggenjurgan B. Critical limb ischemia and its impact on patient health preferences and quality of life-an international study. *Int J Angiol* 2012;21:139–46. [PubMed: 23997557]
75. Tolva VS, Casana R, Lonati L, Invitti C, Bertoni GB, Bianchi PG, et al. Percutaneous transluminal angioplasty improves glucose control and quality of life in patients with critical limb ischemia. *Eur Rev Med Pharmacol Sci* 2012;16:2082–7. [PubMed: 23280023]
76. Nordanstig J, Karlsson J, Pettersson M, Wann-Hansson C. Psychometric properties of the disease-specific health-related quality of life instrument VASCUQOL in a Swedish setting. *Health Qual Life Outcomes* 2012;10:45. [PubMed: 22545952]
77. Bosma J, Turkcan K, Assink J, Wisselink W, Vahl AC. Long-term quality of life and mobility after prosthetic above-the-knee bypass surgery. *Ann Vasc Surg* 2012;26:225–32. [PubMed: 21945332]
78. Laird JR Jr, Yeo KK, Rocha-Singh K, Das T, Joye J, Dippel E, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the salvage study. *Catheter Cardiovasc Interv* 2012;80:852–9. [PubMed: 22422738]
79. Frans FA, Met R, Koelemay MJ, Bipat S, Dijkgraaf MG, et al. Changes in functional status after treatment of critical limb ischemia. *J Vasc Surg* 2013;58:957–965.e951. [PubMed: 24075105]
80. Bosma J, Vahl A, Wisselink W. Systematic review on health-related quality of life after revascularization and primary amputation in patients with critical limb ischemia. *Ann Vasc Surg* 2013;27:1105–14. [PubMed: 23988544]
81. Tshomba Y, Psacharopulo D, Frezza S, Marone EM, Astore D, Chiesa R. Predictors of improved quality of life and claudication in patients undergoing spinal cord stimulation for critical lower limb ischemia. *Ann Vasc Surg* 2014;28:628–32. [PubMed: 24342447]
82. Landry GJ, Esmonde NO, Lewis JR, Azarbal AF, Liem TK, Mitchell EL, et al. Objective measurement of lower extremity function and quality of life after surgical revascularization for critical lower extremity ischemia. *J Vasc Surg* 2014;60:136–42. [PubMed: 24613190]
83. Engelhardt M, Spech E, Diener H, Faller H, Augustin M, Debus ES. Validation of the diseasespecific quality of life Wuerzburg Wound Score in patients with chronic leg ulcer. *VASA* 2014;43:372–9. [PubMed: 25147014]
84. Frans FA, Nieuwkerk PT, Met R, Bipat S, Legemate DA, Reekers JA, et al. Statistical or clinical improvement? Determining the minimally important difference for the vascular quality of life questionnaire in patients with critical limb ischemia. *Eur J Vasc Endovasc Surg* 2014;47:180–6. [PubMed: 24290252]
85. Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M, Pettersson M, Morgan MB. Vascular quality of life questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. *J Vasc Surg* 2014;59:700–7. [PubMed: 24342060]
86. Sultan S, Hynes N. Contemporary management of critical lower limb ischemia in TASC D lesions with subintimal angioplasty in femoro-popliteal lesions, tibial angioplasty and sequential compression biomechanical device for infra-inguinal arterial occlusion. Experience and quality of life outcome learned over 25 years. *J Cardiovasc Surg* 2014;55:813–25. [PubMed: 25216216]

87. Karakoyun R, Koksoy C, Sener Z, Gunduz U, Karakas B, Karakoyun M. Comparison of quality of life in patients with peripheral arterial disease caused by atherosclerosis obliterans or Buerger's disease. *Cardiovasc J Africa* 2014;25:124–9.
88. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. In.Pact amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. *Trials* 2014;15:63. [PubMed: 24552184]
89. Alvarez OM, Wendelken ME, Markowitz L, Comfort C. Effect of high-pressure, intermittent pneumatic compression for the treatment of peripheral arterial disease and critical limb ischemia in patients without a surgical option. *Wounds* 2015;27:293–301. [PubMed: 26574751]
90. Ozaki CK, Hamdan AD, Barshes NR, Wyers M, Hevelone ND, Belkin M, et al. Prospective, randomized, multi-institutional clinical trial of a silver alginate dressing to reduce lower extremity vascular surgery wound complications. *J Vasc Surg* 2015;61:419–427.e411. [PubMed: 25175629]
91. Jens S, Conijn AP, Frans FA, Nieuwenhuis MB, Met R, Koelemay MJ, et al. Outcomes of infrainguinal revascularizations with endovascular first strategy in critical limb ischemia. *Cardiovasc Interv Radiol* 2015;38:552–9.
92. Matsumoto T, Tanaka M, Yoshiya K, Yoshiga R, Matsubara Y, Horiuchi-Yoshida K, et al. Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with dvc1–0101. *Sci Rep* 2016;6:30035. [PubMed: 27418463]
93. Rossello X, Pujadas S, Serra A, Bajo E, Carreras F, Barros A, et al. Assessment of inducible myocardial ischemia, quality of life, and functional status after successful percutaneous revascularization in patients with chronic total coronary occlusion. *Am J Cardiol* 2016;117:720–6. [PubMed: 26747733]
94. Sakaki S, Takahashi T, Matsumoto J, Kubo K, Matsumoto T, Hishinuma R, et al. Characteristics of physical activity in patients with critical limb ischemia. *J Phys Ther Sci* 2016;28:3454–7. [PubMed: 28174472]
95. Katsanos K, Spiliopoulos S, Diamantopoulos A, Siablis D, Karnabatidis D, Scheinert D. Wound healing outcomes and health-related quality-of-life changes in the ACHILLES trial: 1-year results from a prospective randomized controlled trial of infrapopliteal balloon angioplasty versus sirolimus-eluting stenting in patients with ischemic peripheral arterial disease. *JACC Cardiovasc Interv* 2016;9:259–67. [PubMed: 26777329]
96. McGillicuddy EA, Ozaki CK, Shah SK, Belkin M, Hamdan A, Barshes N, et al. The impact of vascular surgery wound complications on quality of life. *J Vasc Surg* 2016;64:1780–8. [PubMed: 27473777]
97. Adams GL, Mustapha J, Gray W, Hargus NJ, Martinsen BJ, Ansel G, et al. The liberty study: design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. *Am Heart J* 2016;174:14–21. [PubMed: 26995365]
98. Michel I, De Haro J, Bleda S, Laime IV, Uyaguari J, Acin F. Rationale and design of randomized clinical trial for the assessment of macitentan efficiency as coadjuvant treatment to open and endovascular revascularization in critical limb ischemia. *Clin Med Insights Cardiol* 2016;10:181–5. [PubMed: 27840580]
99. Smith AD, Hawkins AT, Schaumeier MJ, de Vos MS, Conte MS, Nguyen LL. Predictors of major amputation despite patent bypass grafts. *J Vasc Surg* 2016;63:1279–88. [PubMed: 26860641]
100. Lindgren H, Gottsater A, Qvarfordt P, Bergman S. All cause chronic widespread pain is common in patients with symptomatic peripheral arterial disease and is associated with reduced health related quality of life. *Eur J Vasc Endovasc Surg* 2016;52:205–10. [PubMed: 27344484]
101. Kurose S, Matsubara Y, Yoshino S, Nakayama K, Yamashita S, Morisaki K, et al. Influence of internal iliac artery embolization during endovascular aortic repair regarding postoperative sarcopenia and mid-term survival. *Ann Vasc Surg* 2021;74:148–57. [PubMed: 33248242]
102. Iida O, Takahara M, Soga Y, Azuma N, Nanto S, Uematsu M, et al. Prognostic impact of revascularization in poor-risk patients with critical limb ischemia: the Priority Registry (Poorrisk Patients with and without Revascularization Therapy for Critical Limb Ischemia). *JACC Cardiovasc Interv* 2017;10:1147–57. [PubMed: 28595883]

103. Corriere MA, Goldman MP, Barnard R, Saldana S, Stafford JM, Easterling D, et al. Cumulative number of treatment interventions predicts health-related quality of life in patients with critical limb ischemia. *Ann Vasc Surg* 2017;44:41–7. [PubMed: 28479452]
104. Bague N, Julia P, Sauguet A, Pernes JM, Chatelard P, Garbe JF, et al. Femoropopliteal in-stent restenosis repair: midterm outcomes after paclitaxel eluting balloon use (PLAISIR trial). *Eur J Vasc Endovasc Surg* 2017;53:106–13. [PubMed: 27890526]
105. Fang Y, Wei Z, Chen B, Pan T, Gu S, Liu P, et al. A five-year study of the efficacy of purified cd34+ cell therapy for angitis-induced no-option critical limb ischemia. *Stem Cells Transl Med* 2018;7:583–90. [PubMed: 29709112]
106. Wijnand JGJ, Teraa M, Gremmels H, van Rhijn-Brouwer FCC, de Borst GJ, Verhaar MC, et al. Rationale and design of the sail trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia. *J Vasc Surg* 2018;67:656–61. [PubMed: 29242062]
107. Conijn AP, Santema TB, Bipat S, Koelemay MJ, de Haan RJ. Clinimetric evaluation of the vascular quality of life questionnaire in patients with lower limb ischaemia. *Eur J Vasc Endovasc Surg* 2017;53:412–8. [PubMed: 28065441]
108. Hunt BD, Popplewell MA, Davies H, Meecham L, Jarrett H, Bate G, et al. Balloon versus Stenting in Severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. *Trials* 2017;18:224. [PubMed: 28526046]
109. Larsen ASF, Reiersen AT, Jacobsen MB, Klow NE, Nordanstig J, Morgan M, et al. Validation of the vascular quality of life questionnaire - 6 for clinical use in patients with lower limb peripheral arterial disease. *Health Qual Life Outcomes* 2017;15:184. [PubMed: 28938901]
110. Nordanstig J, Pettersson M, Morgan M, Falkenberg M, Kumlien C. Assessment of minimum important difference and substantial clinical benefit with the vascular quality of life questionnaire-6 when evaluating revascularisation procedures in peripheral arterial disease. *Eur J Vasc Endovasc Surg* 2017;54:340–7. [PubMed: 28754429]
111. Palena LM, Diaz-Sandoval LJ, Sultato E, Brigato C, Candeo A, Brocco E, et al. Feasibility and 1-year outcomes of subintimal revascularization with supera((r)) stenting of long femoropopliteal occlusions in critical limb ischemia: the “supersub” study. *Catheter Cardiovasc Interv* 2017;89:910–20. [PubMed: 27862880]
112. Takeji Y, Yamaji K, Tomoi Y, Okazaki J, Tanaka K, Nagae A, et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. *Circ Cardiovasc Interv* 2018;11:e006778. [PubMed: 30006333]
113. Liotta F, Annunziato F, Castellani S, Boddi M, Alterini B, Castellini G, et al. Therapeutic efficacy of autologous non-mobilized enriched circulating endothelial progenitors in patients with critical limb ischemia- the SCELTA trial. *Circ J* 2018;82:1688–98. [PubMed: 29576595]
114. Klit T, Dahl M, Houliand KC, Ravn H. Effect of impulsive compression treatment on postoperative complications after open peripheral vascular revascularization (in situ): protocol for a randomized control trial. *JMIR Res Protoc* 2018;7:e58. [PubMed: 29463493]
115. Rha SW, Choi SH, Kim DI, Jeon DW, Lee JH, Hong KS, et al. Medical resource consumption and quality of life in peripheral arterial disease in Korea: PAD Outcomes (PADO) research. *Korean Circ J* 2018;48:813–25. [PubMed: 30088358]
116. Rastan A, McKinsey JF, Garcia LA, Rocha-Singh KJ, Jaff MR, Noory E, et al. One-year outcomes following directional atherectomy of infrapopliteal artery lesions: subgroup results of the prospective, multicenter definitive le trial. *J Endovasc Ther* 2015;22:839–46. [PubMed: 26445814]
117. Wang SK, Green LA, Gutwein AR, Drucker NA, Babbey CM, Gupta AK, et al. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites. *J Vasc Surg* 2018;68:560–6. [PubMed: 29503004]
118. Steunenberg SL, de Vries J, Raats JW, Thijssen WJ, Verbogt N, Lodder P, et al. Quality of life and mortality after endovascular, surgical, or conservative treatment of elderly patients suffering from critical limb ischemia. *Ann Vasc Surg* 2018;51:95–105. [PubMed: 29772334]

119. Belowski A, Partyka L, Krzanowski M, Polczyk R, Maga P, Maga M, et al. Clinical and linguistic validation of the polish version of VASCUQOL: a disease-specific quality-of-life questionnaire assessing patients with chronic limb ischemia. *Polish Arch Intern Med* 2019;129:167–74.
120. Aitken SJ, Choy OS, Monaro S. A qualitative study exploring patient concerns and values in chronic limb-threatening ischemia. *J Surg Res* 2019;243:289–300. [PubMed: 31254902]
121. Dua A, Rothenberg KA, Lee JJ, Gologorsky R, Desai SS. Six-month freedom from amputation rates and quality of life following tibial and pedal endovascular revascularization for critical limb ischemia. *Vasc Endovasc Surg* 2019;53:212–5.
122. Goueffic Y, Favre JP, Steinmetz E, Ordureau A, Riche VP, Guyomarch B, et al. A randomized controlled trial comparing crude versus heparin-bonded PTFE graft in below the knee bypass surgery for critical limb ischemia (REPLACE trial): design and protocol. *Ann Vasc Surg* 2019;58:115–21. [PubMed: 30769063]
123. Klinkova AS, Kamenskaya OV, Ashurkov AV, Lomivorotov VN. [The effect of spinal cord stimulation on quality of life in patients with critical lower limb ischemia]. *Zh Vopr Neurokhir Im N N Burdenko* 2019;83:57–63. [PubMed: 31339497]
124. Mustapha J, Gray W, Martinsen BJ, Bolduan RW, Adams GL, Ansel G, et al. One-year results of the liberty 360 study: evaluation of acute and midterm clinical outcomes of peripheral endovascular device interventions. *J Endovasc Ther* 2019;26:143–54. [PubMed: 30722718]
125. Peters CM, de Vries J, Veen EJ, de Groot HG, Ho GH, Lodder P, et al. Is amputation in the elderly patient with critical limb ischemia acceptable in the long term? *Clin Interv Aging* 2019;14:1177–85. [PubMed: 31308641]
126. Peters CML, de Vries J, Lodder P, Steunenbergh SL, Veen EJ, de Groot HGW, et al. Quality of life and not health status improves after major amputation in the elderly critical limb ischaemia patient. *Eur J Vasc Endovasc Surg* 2019;57:547–53. [PubMed: 30826247]
127. Schreve MA, Lichtenberg M, Unlu C, Branzan D, Schmidt A, van den Heuvel DAF, et al. Promise international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (limflow) in the treatment of no-option chronic limb ischemia patient. *CVIR Endovasc* 2019;2:26. [PubMed: 32026120]
128. Spooendonk JA, Krol M, Alleman C. The burden of amputation in patients with peripheral arterial disease (PAD) in the Netherlands. *J Cardiovasc Surg* 2020;61:435–44. [PubMed: 31089087]
129. Piotrkowska R, Terech-Skóra S, Mędrzycka-Dąbrowska W, Jarzynkowski P, Król M. Factors determining acceptance of disease and its impact on satisfaction with life of patients with peripheral artery disease. *Nurs Open* 2021;8:1417–23. [PubMed: 33452863]
130. Steunenbergh SL, de Vries J, Raats JW, Verbogt N, Lodder P, van Eijck GJ, et al. Important differences between quality of life and health status in elderly patients suffering from critical limb ischemia. *Clin Interv Aging* 2019;14:1221–6. [PubMed: 31371929]
131. Teichgraber U, Lehmann T, Thieme M, Wahl KU, Stelzner C, Bormann A, et al. Drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb ischaemia: 1-year results of the apollo trial. *Cardiovasc Interv Radiol* 2019;42:1380–90.
132. Wachsmann A, Maga M, Schonborn M, Olszewska M, Blukacz M, Cebenkenko M, et al. Impact of pre-operative glycosylated haemoglobin a1c level on 1-year outcomes of endovascular treatment in patients with critical limb ischemia in the course of diabetes mellitus. *Folia Med Cracoviensia* 2019;59:49–60.
133. Mustapha JA, Igyarto Z, O'Connor D, Armstrong EJ, Iorio AR, Driver VR, et al. One-year outcomes of peripheral endovascular device intervention in critical limb ischemia patients: sub-analysis of the liberty 360 study. *Vasc Health Risk Manage* 2020;16:57–66.
134. Sasajima T, Sasajima Y, Akazawa K, Saito Y. Arterial reconstruction for patients with chronic limb ischemia improves ambulatory function and health-related quality of life. *Ann Vasc Surg* 2020;166:518–28.
135. Fang G, Jiang X, Fang Y, Pan T, Liu H, Ren B, et al. Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience. *Stem Cell Res Ther* 2020;11:458. [PubMed: 33115517]

136. Giannopoulos S, Mustapha J, Gray WA, Ansel G, Adams G, Secemsky EA, et al. Three-year outcomes from the liberty 360 study of endovascular interventions for peripheral artery disease stratified by Rutherford category. *J Endovasc Ther* 2020. 1526602820962972.
137. Khalil E, Ozcan S. Health-related quality of life after vascular surgery and endovascular treatment in subjects with critical limb ischemia. *Pakistan J Med Sci* 2020;36:877–83.
138. Larsen ASF, Reiersen AT, Nadland IH, Wesche J. Self-reported health status and disease-specific quality of life one year after treatment for peripheral arterial disease in clinical practice. *Health Qual Life Outcomes* 2020;18:235. [PubMed: 32680523]
139. Peeters Weem SM, Teraa M, den Ruijter HM, de Borst GJ, Verhaar MC, Moll FL. Quality of life after treatment with autologous bone marrow derived cells in no option severe limb ischemia. *Eur J Vasc Endovasc Surg* 2016;51:83–9. [PubMed: 26511056]




Fig 1. Number of chronic limb-threatening ischemia (CLTI) studies reporting a Patient-reported Outcome Measure (PROM), by year.




Fig 2. Key terminology and domains in chronic limb-threatening ischemia (CLTI) Patient-reported Outcome Measure (PROM) development.




Fig 3. Steps in developing a chronic limb-threatening ischemia (*CLTI*) Patient-reported Outcome Measure (PROM).

Table 1. Disease-specific quality of life (QoL) instruments used for the study of chronic limb-threatening ischemia

Instrument	No. of items	Scoring system	Domains/subscales	Content validity	Construct validity	Internal consistency	Test-retest reliability	Sensitivity to change	Minimal clinically important difference	Time to administer	Self-administered vs interviewer-administered	Remarks	References
Vascu-QoL	25	1 to 7	Pain, symptoms, activities, emotional well-being, social well-being	Developed based on expert opinion and patient focus groups (Morgan)	IC/CLI Correlations with Fontaine class, SF-36 (Morgan)	Alpha 0.7–0.8 for all items (Morgan)	ICC 0.94 (Morgan)	Statistically significant changes in score with clinical/hemodynamic changes (Morgan, Mazari)	0.36 (Frans), 0.58 (Nordanstig), 0.87 for improvement and 0.23 for deterioration in IC population (Conijn)	10 min	Self-administered	Shorter version (VascuQoL-6) available	Morgan J Vasc Surg, 2001; Conijn Cardiovasc Intervent Radiol, 2015; Frans Eur J Vasc Endovasc Surg 2014; Nordanstig Health Qual Life Outcomes, 2012; Mazari J Vasc Surg, 2010
WIQ	14	0 to 100	Stair climbing, ambulation distance and speed	Unknown	IC. Statistically significant correlations with 6-min walk time and 4-m walk (McDermott)	Alpha 0.29 for pain subscale, other subscales 0.91–0.94 (Coyne)	ICC 0.68–0.83 (Coyne)	Responsiveness statistic 2.1–2.9 (Spertus)	0.11 for improvement and –0.03 for deterioration (Conijn)	6–8 min	Self-administered	Not true QoL measure, assesses only perception of walking	McDermott J Vasc Surg, 1998; Spertus Am J Heart, 2004; Coyne J Vasc Surg, 2003; Conijn Cardiovasc Intervent Radiol, 2015
Peripheral artery questionnaire	20	0 to 100	Physical limitation, symptoms, stability, social limitation, QoL	Based on clinician and patient interviews (Spertus)	IC. Statistically significant correlation with domains of WIQ and SF-36 (Spertus)	Alpha 0.80–0.94 (Spertus)	ICC 0.70–0.90 (Spertus)	Responsiveness statistic 0.7 (treatment remainder were 1.9–4.1 (Spertus)	–	–	Self-administered	Includes unusual domains (eg, symptom stability)	Spertus Am Heart J, 2004

Instrument	No. of items	Scoring system	Domains/subscales	Content validity	Construct validity	Internal consistency	Test-retest reliability	Sensitivity to change	Minimal clinically important difference	Time to administer	Self-administered vs interview-administered	Remarks	References
Peripheral artery disease quality of life	38	0 to 100	Self-concept and feelings, symptoms/limitations in physical functioning, fear and uncertainty, positive adaptation	Based on patient interviews (Treat-Jacobson)	IC/CLL. Statistically significant correlation with domains of SF-36; POMS, WIQ (Treat-Jacobson)	Alpha 0.73–0.92 (Treat-Jacobson)	–	–	–	5–10 min	Self-administered	Includes unusual domains (eg, fear and uncertainty)	Treat-Jacobson Vasc Med, 2012
NeuroQoL	28		Painful symptoms, reduced feeling, diffuse sensorimotor symptoms, disruption of daily activities, interpersonal emotional burden, QoL	Based on clinician and patient interviews (Vileikyte)	Diabetic peripheral neuropathy. Used mediation studies to demonstrate construct validity, eg, NeuroQoL explained a greater portion of QoL than SF-12 (Vileikyte)	Alpha 0.88–0.95 (Vileikyte)	–	–	–	–	Self-administered		Vileikyte Diabetes Care, 2003
Questionnaire on quality of life with chronic wounds	17	0 to 4	Physical limitation, impaired mobility, daily life, leisure, social life, wound discharge, smell, appearance, psychological impairment, feeling disabled, expectation of wound course, being dependent, impairment owing to treatment, financial burden	Based on patient response to other instruments followed by expert consensus (Blome)	Adults with chronic wounds. Statistically significant correlation with domains of EQ-5D-3L, EuroQoL visual analog scale, and numerical rating scale for satisfaction with QoL	Alpha 0.71–0.91 (Blome)	ICC 0.79–0.86 (Sommer)	Correlation coefficients with domains of other tests weak to moderate (r = –0.12 to 0.51) (Blome)	–	–	Self-administered		Blome Wound Repair Regen, 2014; Sommer Wound Repair Regen, 2017

VA Author Manuscript

VA Author Manuscript

VA Author Manuscript

IC/CLI, Intermittent claudication/critical limb ischemia; *ICC*, intraclass correlation coefficient; *NeuroQoL*, Quality of life in neurological disorders; *QoL*, quality of life; *SF-36*, Short Form 36; *Vascu-QoL*, King's College Hospital's vascular quality of life questionnaire; *W/Q*, Walking impairment questionnaire.

Table II.

Currently enrolling chronic limb-threatening ischemia (CLTI) trials

Study name	ClinicalTrials.gov identifier	Study status	Start of enrollment	PROMS
Exercise rehabilitation for patients with critical ischemia after revascularization	NCT03839953	Enrolling	2/15/2019	Vascu-QoL, SF-36
Administration of adipose-derived stem cells in patients with critical limb ischemia	NCT03968198	Enrolling	3/4/2020	Pain score (visual analogue)
Revascularization of stenosed vessels using optimized treatment of Rejuvenix for reversing endothelial dysfunction	NCT03041259	Not yet enrolling		Walking impairment questionnaire
Physician Initiated, Prospective, Non-randomized Single-centre, Single-arm Trial, Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infrainguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore (PINNACLE)	NCT04534192	Not yet enrolling		Walking impairment questionnaire
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia	NCT04274049	Enrolling	8/18/2019	Pain score (unspecified)
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia	NCT04275323	Enrolling	8/2/2019	Pain score (numerical rating scale), QoL (unspecified instrument)
Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia	NCT02993809	Unknown	3/10/18	Pain score (visual analogue)
Intermittent Negative Pressure: Impact on Peripheral Artery Disease and Intermittent Claudication	NCT04100681	Terminated	8/19/2019	EQ-5D, VascuQoL-6, change in pain-free walking distance
Smartstep Smartphone PAD	NCT03479255	Enrolling	8/24/2018	SF-36, walking impairment questionnaire, 6-minute walk test
Recombinant SeV-hFGF2/dF Injection for PAOD	NCT03668353	Unknown	9/5/2018	Pain score (visual analogue), walking distance (unspecified)
Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)	NCT04083755	Enrolling	8/15/2019	SF-36
Leg Ischaemia Management Collaboration (LIMb)	NCT04027244	Enrolling	5/10/2019	Vascu-QoL, Barthel Index (disability), Hospital Anxiety and Depression Scale
RECCORD (Recording Courses of Vascular Diseases) Registry (RECCORD)	NCT03448029	Enrolling	1/1/2018	EQ-5D
Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-opton Ischemic Limbs (SAIL)	NCT03042572	Not yet enrolling		EQ-5D, Pain (visual analogue), pain-free walking distance, SF-36
BIO RESPONSE Adapted Combination Therapy Pilot Study	NCT03547986	Active, not enrolling	11/9/2018	EQ-5D, walking impairment questionnaire
ILLUMENATE Pivotal Post-Approval Study (PAS)	NCT03421561	Active, not enrolling	4/14/2017	EQ-5D, walking impairment questionnaire, walking distance
Autologous BMMNC Combined With HA Therapy for PAOD	NCT03214887	Unknown	1/17/2017	Pain (visual analogue), pain-free walking distance
Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon (SWING)	NCT04107298	Not yet enrolling		EQ-5D, VascuQoL, walking impairment questionnaire

Study name	ClinicalTrials.gov identifier	Study status	Start of enrollment	PROMS
Stella Supera Siberia	NCT03951727	Enrolling	5/13/2019	EQ-5D
BEST-CLI	NCT02060630	Completed		EQ-54, VasuQoI
Basil-2	ISRCTN:27728689	Enrolling		European Quality of Life questionnaire, SF-12
Basil-3	ISRCTN:27728689	Enrolling		European Quality of Life questionnaire, SF-12
Shifting Care and Outcomes for Patients with Endangered Limbs	NCT03171259	Enrolling		Peripheral Artery Questionnaire
SWEDEPAD-2 (The Swedish Drug Elution Trial in Peripheral Artery Disease)	NCT02051088	Enrolling		
Study period: 01/01/2017-09/10/2020 (3 full years + current year)				
Search: peripheral arterial disease, peripheral vascular disease, critical limb ischemia, chronic limb threatening ischemia				
“Primary outcome measures” and “Secondary outcome measures” analyzed for PROMs				

PROMS, Patient-Reported Outcomes; *SF-36*, Short Form 36; *Vascul-QoI*, King’s College Hospital’s vascular quality of life questionnaire.

Table III.

Barriers to the design and implementation of Patient-Reported Outcomes (PROMs) for chronic limb-threatening ischemia (CLTI)

Challenge or barrier to measure development	Questions
Overall purpose	Are the measures clinically justified? Are the measures clinically applicable?
Measure format	Are the questions comprehensible and simple? Are the directions for usage clear? Is the survey thorough?
Face validity	Are the questions aimed at the right thing (ie, QoL)?
Content validity	Have important variables/questions been omitted? Have unsuitable variables/questions been included? Are appropriate score ranges used for questions?
Ease of use	How much time and effort are required to obtain and organize data (i.e., answer the survey)?